TLSI · CIK 1826667
What TriSalus Life Sciences, Inc. told the SEC could break it.
TriSalus's risks orbit a single product: substantially all of its revenue comes from the TriNav device ($45.2 million, up 53.4% in 2025), so its fortunes track that one product's market acceptance and reimbursement. Both of those are exposed to forces it doesn't fully control — it may rely on sole-source third parties for the materials and finished products behind TriNav, and TriNav's sales depend on specific Medicare HCPCS reimbursement codes whose downgrade could materially cut sales. Funding carries weight too: $35.0 million of senior secured term debt under its OrbiMed agreement, secured by substantially all its assets, plus up to $158.0 million of contingent Dynavax milestone obligations.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- Single-product dependence on the TriNav devicehigh
Substantially all revenue is generated from a single product, the TriNav device ($45.2M, 53.4% growth in 2025), so any decline in TriNav market acceptance or reimbursement would materially harm the business.
“Our revenue is primarily generated from sales of our TriNav device and we are therefore highly dependent on it for our success.”
SEC filing →As of 2026
Sole-source dependency
- Sole-source third-party suppliers/manufacturers for materials and finished productshigh
TriSalus may rely on certain third parties as the sole source of materials they supply or finished products they manufacture, including for product candidates; disruption at those suppliers could impair commercialization and clinical trials.
“We may rely on certain third parties as the sole source of the materials they supply or the finished products they manufacture. We may also have sole-source suppliers for one or more of our other product candidates.”
SEC filing →As of 2026
Liquidity & debt
- OrbiMed senior secured term debt and contingent Dynavax milestone obligationsmedium
TriSalus borrowed $35.0M senior secured term debt under the OrbiMed Credit Agreement, secured by substantially all of its assets and subject to restrictive covenants, on top of up to $158.0M of contingent Dynavax milestone payments.
“We have entered into the OrbiMed Credit Agreement and borrowed $35.0 million senior secured term debt. Our obligations under the OrbiMed Credit Agreement are secured by substantially all of our assets.”
SEC filing →As of 2026
Regulatory & policy
- Dependence on CMS/HCPCS reimbursement status for TriNavmedium
TriNav sales depend on Medicare HCPCS reimbursement codes (C9797, C8004); any change reducing the level of reimbursement could cause sales to materially decline and impede market adoption.
“Any change to TriNav's reimbursement status that reduces our level of reimbursement could cause TriNav sales to materially decline and impede market adoption.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Dynavax Technologies Corporation
“Pursuant to the Dynavax Agreement, as of the date of this Annual Report, we have paid Dynavax $12.0 million to date and we may be required to pay Dynavax up to an additional $158.0 million upon the achievement of certain development and regulatory milestones”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch